Viewing nowAlpicloprid Tablet (Clopidogrel Bisulfate)
Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Alpibio Co., Ltd.

MFDS item code 201306524 · Approved 2013.03.29 · Insurance code 661604090
Improvement of symptoms of acute coronary syndrome and atherosclerosis, and reduction of the risk of thromboembolism in atrial fibrillation
This medication is used to improve symptoms in adult patients with atherosclerotic conditions such as ischemic stroke, myocardial infarction, and peripheral arterial disease. Additionally, it helps prevent and improve cardiovascular complications in adult patients with acute coronary syndrome, especially those with unstable angina or non-ST elevation myocardial infarction who have received or are scheduled to receive drug therapy or coronary interventions. It is effective in reducing the risk of stroke and thromboembolism in atrial fibrillation patients with one or more vascular risk factors for which vitamin K antagonists are not suitable due to low bleeding risk. In this way, it manages various risk factors associated with cardiovascular diseases to stabilize patients' health and improve symptoms.
○ Adults 1. For patients with ischemic stroke, myocardial infarction, or peripheral arterial disease, administer 75 mg of clopidogrel orally once daily. 2. For patients with acute coronary syndrome (unstable angina or non-Q-wave myocardial infarction), start with a loading dose of 300 mg of this medicine orally once daily on the first day of treatment, followed by a maintenance dose of 75 mg orally once daily. Aspirin 75 ~ 325 mg must be administered concomitantly with this medicine once daily. 3. For patients with atrial fibrillation, administer 75 mg of this medicine orally once daily. Aspirin 75 ~ 100 mg must be administered concomitantly with this medicine once daily. ○ Patients with renal impairment: Experience with treatment in patients with renal impairment is limited. ○ Patients with hepatic impairment: Experience with treatment in patients with moderate hepatic disease and a bleeding diathesis is limited. This medicine may be administered with or without food.
This medication prevents the clumping of platelets in the blood, thus preventing thrombosis. However, it must be converted into an active metabolite by a specific enzyme (CYP2C19) in the liver to be effective. Individuals genetically deficient in this enzyme may experience reduced effects, and treatment options may need to be reconsidered. Additionally, co-administration with drugs that activate this enzyme may increase the concentration of the active ingredient, elevating bleeding risk, thus co-administration should be avoided. This medication should not be used in patients with bleeding, severe liver damage, breastfeeding women, or patients with certain lactose-related genetic disorders. Patients at high risk of bleeding or with coagulation issues should use this medication cautiously, and if surgery is planned, it should be discontinued 5-7 days prior. If any bleeding symptoms occur, immediately inform a doctor and undergo blood tests. The use of this medication in conjunction with other antiplatelet agents, anticoagulants, non-steroidal anti-inflammatory drugs (NSAIDs), and selective serotonin reuptake inhibitors (SSRIs) may increase bleeding risk, thus caution is advised. While no fetal effects have been reported during pregnancy, bleeding risk during delivery may be increased, and it is advisable to stop the medication 5-7 days before delivery. During breastfeeding, as the drug may be excreted in breast milk, either breastfeeding should be discontinued or the medication should be stopped. Elderly patients or those with impaired kidney or liver function may have a higher risk of bleeding, requiring dosage adjustments and monitoring of their condition. Overdosage of this medication may prolong bleeding time and result in bleeding complications, requiring immediate medical attention, and platelet transfusion may reverse the drug's effects. During the use of this medication, abnormal symptoms such as bleeding, skin rash, dyspepsia, headache, dizziness, etc., may occur, requiring consultation with a physician if any abnormal symptoms arise. This medication should be stored out of reach of children and should not be transferred to another container for safety.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly sealed container to prevent exposure to air or moisture. Additionally, it is best to store it at room temperature between 1 degree and 30 degrees Celsius. This will help maintain the medication's effectiveness for a longer duration.
Pink, round, film-coated tablet
30 tablets/bottle, 100 tablets/bottle
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowClopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Alpibio Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Geonil Pharmaceutical Co., Ltd.
Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Sama Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Il Yang Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Korea Union Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
(Co., Ltd.) Korea Pharma

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Samjin Pharmaceutical Co., Ltd.

Clopidogrel Bisulfate 97.875mg
Tablet · Prescription medication
Daewon Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.